This application relates generally to anatomical implants, and more specifically, to hydrogel joint implants and various tools, devices, systems and methods related thereto.
Implants are often used to replace deteriorated or otherwise damaged cartilage within a joint. Such devices can be used to treat osteoarthritis, rheumatoid arthritis, other inflammatory diseases, generalized joint pain and/or other joint diseases. To ensure proper function and long term effectiveness, such implants should be properly secured within a patient's bone or other implant site.
According to some embodiments, a method of treating a joint of a patient comprising creating a recess, hole or other opening in a bone located at or near a targeted joint, wherein the recess comprises a generally wedge, reverse tapered, truncated cone shape and/or other shape in which the bottom of the recess comprises a larger diameter or other cross-sectional dimension than a top of the recess. In some embodiments, the recess or other opening in the bone comprises a surface opening along an outer surface of the bone, a bottom opening along the distal end of the recess and side walls that generally extend between the surface opening and the bottom opening, wherein a diameter or other cross-sectional dimension of the bottom opening is larger than a diameter or other cross-sectional dimension of the surface opening.
According to some embodiments, the method further comprises at least partially radially compressing a joint implant having wedge or truncated cone shape, wherein the joint implant comprises a first end and a second end and a body extending between the first end and the second end. In some embodiments, the second end of the implant is generally opposite of the implant's first end. In one embodiment, when the joint implant is in a radially uncompressed state, a diameter or other cross-sectional dimension of the first end is smaller than a diameter or other cross-sectional dimension of the second end. The method further comprises inserting the joint implant within the recess, while the joint implant is in a radially compressed state, wherein the second end of the joint implant is inserted first within the recess. In some embodiments, the second end of the joint implant is adjacent the bottom opening of the recess, and the first end of the joint implant is adjacent the surface opening of the recess when the joint implant is properly positioned within the recess. The method further comprises, in some embodiments, releasing the joint implant from a radially compressed state to a less compressed state, when the joint implant is properly positioned within the recess, wherein, when the joint implant is in a less compressed state, the diameter or other cross-sectional dimension of the second end of the joint implant is larger than the diameter or other cross-sectional dimension of the surface opening of the recess. In some embodiments, when the joint implant is in a radially uncompressed state, the body of the joint implant imparts a radial force at least partially along the side walls of the recess, thereby securing the joint implant within the recess.
According to some embodiments, creating the recess in a bone comprises using a drill bit comprising an articulating cutter configured to selectively enlarge the recess near the bottom opening along the distal end of the recess. In some embodiments, creating the recess comprises moving a sleeve of the drill bit so as to radially expand the articulating cutter outwardly at or near the distal end of the recess. In one embodiment, the drill bit is cannulated, wherein the drill bit is positioned over a guide pin to place a working end of the drill bit near a targeted location of the recess.
According to some embodiments, the joint implant is radially compressed and inserted within the recess using an introducer. In some embodiments, the joint implant is urged through an interior of the introducer using a plunger or other pusher member. In some embodiments, the joint implant is urged through an interior of the introducer using a mechanically-assisted device. In some embodiments, the mechanically-assisted device comprises a handle and a clamp coupled to the handle, wherein moving the clamp relative to the handle urges a plunger within an introducer to radially compress the joint implant and insert the joint implant within the recess. In some embodiments, the clamp is rotatably coupled to the handle. In some embodiments, an interior of the introducer is polished to further reduce friction. In some embodiments, movement of the implant through an introducer is facilitated with the use of a vacuum source, a pressure source and/or any other pneumatic, mechanical, electrical and/or other device.
According to some embodiments, the joint implant comprises a hydrogel, such as, for example, polyvinyl alcohol (PVA), other polymeric materials and/or the like. In some embodiments, a content of PVA and/or any other polymeric component of the hydrogel is approximately 20% to 60% by weight (e.g., about 20, 25, 30, 35, 40, 45, 50, 55, 60%, values between the foregoing percentages, etc.). In some embodiments, a content of PVA and/or any other polymeric component of the hydrogel is less than approximately 20% or greater than approximately 60% by weight. In some embodiments, a ratio of the diameter or other cross-sectional dimension of the second end of the joint implant to the diameter or other cross-sectional dimension of the first end of the joint implant is approximately between approximately 1.05 and 1.3 (e.g., about 1.05, 1.1, 1.15, 1.2. 1.25, 1.3, ratios between the foregoing, etc.). In other embodiments, a ratio of the diameter or other cross-sectional dimension of the second end of the joint implant to the diameter or other cross-sectional dimension of the first end of the joint implant is less than approximately 1.05 or greater than approximately 1.3. In some embodiments, a ratio of the diameter or other cross-sectional dimension of the second end of the joint implant to the diameter or other cross-sectional dimension of the first end of the joint implant is at least about 1.1
According to some embodiments, the diameter or other cross-sectional dimension of the second end of the implant is approximately 5% to 25% larger (e.g., about 5, 10, 15, 20, 25%, values between the foregoing percentages, etc.) than the diameter or other cross-sectional dimension of the implant. In some embodiments, the diameter or other cross-sectional dimension of the second end of the implant is less than approximately 5% or greater than approximately 25% of the diameter or other cross-sectional dimension of the implant. In some embodiments, the recess is located within or near at least one of a toe, finger, ankle, knee, shoulder, hip or any other joint. In some embodiments, the top end of the joint implant is approximately 5 mm to 20 mm (e.g., about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 mm, values between the foregoing, etc.) in diameter or in other cross-sectional dimension. In some embodiments, the top end of the joint implant is greater than approximately 20 mm or smaller than approximately 5 mm (e.g., about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.9 mm, ranges between the foregoing, less than about 1 mm, etc.).
According to some embodiments, an implant configured for implantation within a joint of a patient comprises a top end configured to form an articulation surface when properly implanted within a joint, a bottom end generally opposite of the top end and a main hydrogel body extending between the top end and the bottom end and having a longitudinal centerline. In some embodiments, such an implant comprises a hydrogel (e.g., PVA) implant or any other type of substrate-based implant. In some embodiments, such an implant can be used in any of the joint treatment methods disclosed herein. In some embodiments, a diameter or a cross-sectional dimension of the bottom end is greater than a diameter or a cross-sectional dimension of the top end. In one embodiment, side walls generally extend between the top end and the bottom end of the implant, wherein the side walls are generally sloped relative to the longitudinal centerline. In some embodiments, the implant comprises a tapered shape due to, at least in part, to a difference between the diameters or cross-sectional dimensions of the top end and the bottom end. In some embodiments, the implant is configured for placement within an implant site having a similar reverse tapered shape, thereby reducing the likelihood of unintentional removal of the implant from the implant site following implantation.
According to some embodiments, the hydrogel comprises polyvinyl alcohol (PVA) and/or any other polymeric material. In some embodiments, the content of PVA in the hydrogel is approximately 35% to 45% by weight (e.g., about 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45%, values between the foregoing, etc.). In other embodiments, the content of PVA in the hydrogel is greater than approximately 45% by weight (e.g., about 45, 50, 55, 60, 65, 70%, greater than about 70%, ranges between the foregoing values, etc.) or less than approximately 35% by weight (e.g., 5, 10, 15, 20, 25, 30, 35%, ranges between the foregoing values, less than about 5%, etc.). According to one embodiment, the content of PVA or other component in the hydrogel is approximately 40% by weight. In some embodiments, the implant is load bearing and generally non-biodegradable. In some embodiments, the implant is configured for placement within at least one of a toe, finger, ankle, knee, shoulder, hip or any other joint. In some embodiments, a transition between the top end and the side walls is generally curved or otherwise smooth.
According to some embodiments, the top end of the implant is approximately 5 mm to 20 mm in diameter or other cross-section dimension (e.g., about 5, 10, 15, 20 mm, ranges between the foregoing values, etc.). In other embodiments, the top end of the implant is greater than about 20 mm (e.g., 25, 30, 35, 40 mm, greater than 40 mm, etc.) or smaller than about 5 mm (e.g., 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5 mm, ranges between the foregoing, less than about 1 mm, etc.). In some embodiments, a diameter of the bottom end is approximately 5% to 25% larger than a diameter of the top end (e.g., about 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25%, ranges between the foregoing, less than about 5%, greater than about 25%, etc.). In some embodiments, a diameter of the bottom end is approximately 10% to 15% larger than a diameter of the top end (e.g., about 10, 11, 12, 13, 14, 15%, ranges between the foregoing, less than about 10%, greater than about 15%, etc.).
According to some embodiments, a distance between the top end and the bottom end of the implant is approximately 4 mm to 16 mm (e.g., about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 mm, values between the foregoing, etc.). In other embodiments, a distance between the top end and the bottom end of the implant is less than approximately 4 mm (e.g., less than 1 mm, about 1 mm, about 2 mm, about 3 mm, about 4 mm, ranges between the foregoing, etc.) or greater than approximately 16 mm (e.g., about 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 35, 40, 45, 50 mm, greater than about 50 mm, etc.). In some embodiments, a ratio of the diameter or other cross-sectional dimension of the bottom end of the implant to the diameter or other cross-sectional dimension of the top end of the implant is approximately between 1.05 and 1.3 (e.g., about 1, 1.05, 1.1, 1.15, 1.2, 1.25, 1.3, ranges between the foregoing, etc.). In some embodiments, a ratio of the diameter or other cross-sectional dimension of the bottom end of the implant to the diameter or other cross-sectional dimension of the top end of the implant is greater than about 1.3 (e.g., about 1.3, 1.35, 1.4, 1.45, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, greater than about 2.0, ranges between the foregoing, etc.). In some embodiments, a ratio of the diameter or other cross-sectional dimension of the bottom end of the implant to the diameter or other cross-sectional dimension of the top end of the implant is at least about 1.1.
According to some embodiments, a drill bit configured to be used with a bone drill to make a reverse taper recess within a bone along or near a joint of a patient comprises a main body comprising a proximal end and a distal end. Such a drill bit or other tool can be used in the method of treating a joint and/or prior to delivering a reverse tapered implant into the anatomy, in accordance with the disclosure provided herein. In some embodiments, the proximal end of the main body is configured to couple to a driving portion of a bone drill in order to selectively rotate said drill bit. In some embodiments, the drill bit or other tool comprises a flange located along the distal end of the main body and one or more (e.g., two, three, four, more than four) stationary cutters extending distally from the flange, wherein the one or more stationary cutters are configured to create a generally cylindrical opening within a bone. In some embodiments, the drill bit or other tool further comprises at least one articulating cutter extending distally from the flange, wherein the articulating cutter is configured to be selectively moved between a stowed position and a radially extended position, and wherein the articulating cutter is configured to create a reverse taper, wedge, truncated cone or similarly shaped recess within a bone when in the radially extended position, wherein a diameter or other cross-sectional dimension of a bottom opening of the recess is larger than a diameter or other cross-sectional dimension of a surface opening of the recess.
According to some embodiments, wherein the drill bit comprising at least one articulating cutter is inserted within a generally cylindrical recess created by a first bit, wherein a reverse taper or similarly shaped recess is created within the generally cylindrical recess when the at least one articulating cutter is moved (e.g., extended) to the radially extended position. According to some embodiments, the one or more articulating cutters of the drill bit are coupled to the main body using a hinge or other pivot point. In one embodiment, the articulating cutter is normally resiliently biased in the stowed position. In other embodiments, the articulating cutter is normally resiliently biased in the expanded or extended position. In some embodiments, the drill bit is cannulated or otherwise comprises one or more openings or passages, thereby allowing the drill bit to be placed over a guide pin in order to accurately position the drill bit to a targeted portion of a bone. In some embodiments, the drill bit comprises a sleeve, sheath and/or other outer member configured to be moved relative to the main body, wherein retracting the sleeve radially causes the at least one articulating cutter to be moved from the stowed position and the radially extended position.
According to some embodiments, a mechanically-assisted delivery tool for delivering an implant within a corresponding implant site comprises an introducer tube comprising an inner lumen and a neck portion along a distal end of said introducer tube, wherein the inner lumen of the introducer tube comprises a generally cylindrical portion along a proximal end of the introducer tube and a narrowed portion along the distal end. In some embodiments, the neck portion of the introducer tube is configured to be inserted within a recess or other opening created within an implant site of a patient. In one embodiment, the introducer tube comprises at least one slit or other recess or opening extending at least partially along a length of the introducer tube. In some embodiments, the mechanically-assisted delivery tool comprises a plunger or other movable member configured to be at least partially inserted into and moved within the lumen of the introducer tube. In some embodiments, the tool additionally comprises a handle coupled to the introducer tube, wherein the handle comprises at least one opening. In some embodiments, the tool comprises a clamp comprising a protruding member configured to be inserted within the at least one opening of the handle to couple the clamp to the handle.
According to some embodiments, the clamp is rotatably movable relative to the handle by movement of the protruding member within the at least one opening. In some embodiments, the clamp is configured to be selectively moved within the at least one slit or other opening of the introducer tube when the clamp is rotated relative to the handle. According to some embodiments, movement of the clamp within the at least one slit toward the distal end of the introducer tube urges the plunger positioned within the inner lumen of the introducer tube to move an implant placed within the lumen of the introducer tube to move within the narrowed portion of the inner lumen, through the neck portion of the introducer tube and within a target implant site. In some embodiments, movement of the implant within the narrowed portion of the inner lumen radially compresses the implant.
According to some embodiments, the introducer tube, the handle, the clamp and the plunger are configured to be selectively separated from one another to facilitate sterilization, cleaning, repairs, maintenance and/or any other activity relating to the delivery tool. In some embodiments, the introducer tube is coupled to the handle using a threaded connection, a snap-fit connection, a pressure or friction fit connection, a tab, other coupling and/or any other attachment device, system or method. In some embodiments, the narrowed portion of the inner lumen of the introducer tube comprises a generally linear slope. In some embodiments, the narrowed portion of the inner lumen of the introducer tube comprises a generally non-linear (e.g., curved, undulating, rounded, etc.) shape or slope. In some embodiments, the narrowed portion of the inner lumen extends from the generally cylindrical portion to the neck portion of the introducer tube. In some embodiments, a head portion of the plunger comprises a motion limiter to limit movement of the plunger within the inner lumen of the introducer tube to a maximum depth. In one embodiment, a proximal end of the introducer tube comprises a flange or other flared portion.
According to some embodiments, a method of treating a joint of a patient comprises creating a recess in a bone located at or near a targeted joint, wherein the recess comprises a generally wedge, truncated cone or reverse tapered shape. In some embodiments, the recess in a bone comprises a surface opening along an outer surface of the bone, a bottom opening along the distal end of the recess and side walls generally extending between the surface opening and the bottom opening, wherein a diameter or other cross-sectional dimension of the bottom opening is larger than a diameter or other cross-sectional dimension of the surface opening. In one embodiment, the method comprises at least partially radially compressing a joint implant having wedge or truncated cone shape, wherein the joint implant includes a first end and a second end and body extending between the first end and the second end such that the second end is generally opposite of the first end. In some embodiments, when the joint implant is in a radially uncompressed state, a diameter or other cross-sectional dimension of the first end is smaller than a diameter or other cross-sectional dimension of the second end. In some embodiments, while the joint implant is in a radially compressed state, the method additionally comprises inserting the joint implant within the recess, wherein the second end of the joint implant is inserted first within the recess. In one embodiment, the second end of the joint implant is adjacent the bottom opening of the recess, and wherein the first end of the joint implant is adjacent the surface opening of the recess when the joint implant is properly positioned within the recess. In one embodiment, the method comprises releasing the joint implant from a radially compressed state to a less compressed state, when the joint implant is properly positioned within the recess. In one embodiment, when the joint implant is in a less compressed state, the diameter or other cross-sectional dimension of the second end of the joint implant is larger than the diameter or other cross-sectional dimension of the surface opening of the recess. In some embodiments, when the joint implant is in a radially uncompressed state, the body of the joint implant imparts a radial force at least partially along the side walls of the recess, thereby securing the joint implant within the recess.
According to some embodiments, creating the recess in a bone comprises using a drill bit comprising an articulating cutter configured to selectively enlarge the recess near the bottom opening along the distal end of the recess. In one embodiment, creating the recess comprises moving a sleeve of the drill bit so as to radially expand the articulating cutter outwardly at or near the distal end of the recess. In some embodiments, the drill bit is cannulated. In one embodiment, the drill bit is positioned over a guide pin or other guide or positioning member to place a working end of the drill bit at or near a targeted location of the recess. In some embodiments, the joint implant is radially compressed and inserted within the recess using an introducer. In some embodiments, the joint implant is urged through an interior of the introducer using a plunger or other pusher member. In one embodiment, the joint implant comprises a hydrogel. In some embodiments, the hydrogel comprises polyvinyl alcohol (PVA). In one embodiment, a content of PVA and/or other component of the hydrogel is approximately 20% to 60% by weight. In some embodiments, the water content of the hydrogel is approximately 40% to 80% by weight.
According to some embodiments, a ratio of the diameter or other cross-sectional dimension of the second end of the joint implant to the diameter or other cross-sectional dimension of the first end of the joint implant is approximately between 1.05 and 1.3. In some embodiments, a ratio of the diameter or other cross-sectional dimension of the second end of the joint implant to the diameter or other cross-sectional dimension of the first end of the joint implant is at least about 1.1. In one embodiment, the diameter or other cross-sectional dimension of the second end of the implant is approximately 5% to 25% larger than the diameter or other cross-sectional dimension of the implant. In some embodiments, the recess is located within or near at least one of a toe, finger, ankle, knee, shoulder, hip or other joint. In some embodiments, the top end of the joint implant is approximately 5 mm to 20 mm in diameter.
According to some embodiments, a drill bit configured to be used with a bone drill to make a reverse taper or wedge recess within a bone along or near a joint of a patient comprises a main body comprising a proximal end and a distal end, such that the proximal end of the main body is configured to couple to a driving portion of a bone drill in order to selectively rotate said drill bit. According to one embodiment, the drill bit further comprises a flange located along the distal end of the main body. In some embodiments, the drill bit comprises one or more stationary cutters extending distally from the flange, wherein the stationary cutters are configured to create a generally cylindrical opening within a bone. The drill bit further comprises at least one articulating cutter extending distally from the flange, wherein the articulating cutter is configured to be selectively moved between a stowed position and a radially extended position. In one embodiment, the articulating cutter is configured to create a reverse taper or wedge shaped recess within a bone when in the radially extended position, wherein a diameter of a bottom opening of the recess is larger than a diameter of a surface opening of the recess.
According to some embodiments, the drill bit comprising an articulating cutter is inserted within a generally cylindrical recess created by a first bit, such that a reverse taper recess or wedge shape is created within the generally cylindrical recess when the articulating cutter is moved to the radially extended position. In some embodiments, the articulating cutter is coupled to the main body using a hinge or other pivot point. In one embodiment, the at least one articulating cutter is normally resiliently biased in the stowed position. In some embodiments, the drill bit is cannulated, allowing the drill bit to be placed over a guide pin or other positioning member in order to accurately position the drill bit to or near a targeted portion of a bone (e.g., joint). In one embodiment, the drill bit further comprises a sleeve or other movable member configured to be slid or otherwise moved relative to the main body, wherein retracting the sleeve or other member radially causes the articulating cutter to be moved from the stowed position and the radially extended position.
According to some embodiments, a hydrogel implant configured for implantation within a joint of a patient comprises a top end configured to form an articulation surface when properly implanted within a joint, a bottom end generally opposite of the top end and a main hydrogel body extending between the top end and the bottom end and having a longitudinal centerline. In some embodiments, a diameter of the bottom end is greater than a diameter of the top end and side walls generally extend between the top end and the bottom end, such that the side walls are generally sloped relative to the longitudinal centerline. In one embodiment, the implant comprises a tapered shape due to, at least in part, to a difference between the diameters of the top end and the bottom end. In some embodiments, the implant is configured for placement within an implant site having a similar reverse tapered or wedge shape, thereby reducing the likelihood of unintentional removal of the implant from the implant site following implantation.
According to some embodiments, the hydrogel comprises polyvinyl alcohol (PVA) and/or another substance or additive. In some embodiments, the content of PVA and/or other substances is approximately 10% to 80% (e.g., about 35% to 45%) by weight. In some embodiments, the content of PVA is approximately 40% by weight. In one embodiment, the content of water and/or saline in the hydrogel is 60% by weight. In one embodiment, the implant is load bearing and generally non-biodegradable. In some embodiments, the implant is configured for placement within at least one of a toe, finger, ankle, knee, shoulder, hip or other joint. In some embodiments, a transition between the top end and the side walls is generally curved or otherwise smooth. In one embodiment, the top end of the implant is approximately 5 mm to 20 mm in diameter. In some embodiments, a diameter of the bottom end is approximately 5% to 25% larger than a diameter of the top end. In one embodiment, a diameter of the bottom end is approximately 10% to 15% larger than a diameter of the top end. In some embodiments, a distance between the top end and the bottom end of the implant is approximately 4 mm to 16 mm. In one embodiment, a ratio of the diameter or other cross-sectional dimension of the bottom end of the implant to the diameter or other cross-sectional dimension of the top end of the implant is approximately between 1.05 and 1.3. In one embodiment, a ratio of the diameter or other cross-sectional dimension of the bottom end of the implant to the diameter or other cross-sectional dimension of the top end of the implant is at least 1.1.
According to some embodiments, a hydrogel implant configured for implantation within a joint of a patient comprises a top end configured to form an articulation surface when properly implanted within a joint, a bottom end generally opposite of the top end and a main hydrogel body extending between the top end and the bottom end and having a longitudinal centerline. In one embodiment, a diameter of the bottom end is greater than a diameter of the top end. The implant additionally comprises side walls that generally extend between the top end and the bottom end, wherein the side walls are generally sloped relative to the longitudinal centerline of the implant. In some embodiments, the implant comprises a tapered shape or frustum due to, at least in part, to a difference between the diameters of the top end and the bottom end. In one embodiment, the implant is configured for placement within an implant site having a similar reverse tapered, wedge or truncated cone shape or frustum, thereby reducing the likelihood of unintentional removal of the implant from the implant site following implantation.
According to some embodiments, the hydrogel comprises polyvinyl alcohol (PVA), saline, water, another hydrogel material, another polymeric material and/or any other substance or additive. In some embodiments, the content of PVA in the implant is approximately 20% to 60% by weight. In one embodiment, the content of PVA in the implant is approximately 40% by weight. In some embodiments, the implant is generally load bearing and/or configured for long term implantation within a patient. In one embodiment, the implant is generally non-biodegradable.
According to some embodiments, the joint implant is configured for placement within a toe, finger, ankle, knee, shoulder, hip and/or any other joint. In one embodiment, a transition between the top end and the side walls is generally curved or otherwise smooth. In some embodiments, the top end of the implant is approximately 5 mm to 20 mm in diameter. In some embodiments, a diameter of the bottom end is approximately 5% to 15% (e.g., about 10%, 11%, 12%, 13%, 14%, 15%, etc.) larger than a diameter of the top end of the implant. In some embodiments, a distance between the top end and the bottom end of the implant is approximately 4 mm to 16 mm.
According to some embodiments, a method of treating a joint of a patient comprises creating a recess in a bone located at or near a targeted joint, wherein the recess includes a generally wedge or truncated cone shape. In one embodiment, the recess in a bone comprises a surface opening along an outer surface of the bone and a bottom opening along the distal end of the recess, such that a diameter of the surface opening is generally smaller than a diameter of the bottom opening. The method additionally comprises providing a joint implant having a wedge or truncated cone shape, wherein a diameter of a top end of the joint implant is generally smaller than a diameter of a bottom end of the joint implant. The method further includes inserting the joint implant within the recess so that the bottom end of the joint implant is adjacent to the bottom opening of the recess. In some embodiments, the diameter of the bottom end of the joint implant is larger than the diameter of the surface opening of the recess. In some embodiments, the size of the implant matches or substantially matches the size of the recess. In some embodiments, the size of the implant is larger (e.g., nominally, significantly, etc.) than the size of the recess. Accordingly, in such arrangements, the implant remains at least partially radially compressed within after implantation into the target recess or other implant site. The amount of radial compression in the implant after implantation into the recess can vary from approximately 0% to about 20% (e.g., about 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, values between the foregoing percentages, etc.). In one embodiment, for example, the compression ratio of an implant is approximately 10%, wherein the diameter (or other cross sectional dimension) of the recess base is about 90% of the base or bottom diameter of the implant.
According to some embodiments, the step of creating a recess in a bone comprises using a drill bit comprising an articulating cutter configured to create the generally wedge or truncated cone shape in the recess. In one embodiment, the joint implant is inserted within the recess using an introducer. In some embodiments, the joint implant is urged through an interior of the introducer using a plunger or other pusher member (e.g., manually or with the assistance of mechanical, hydraulic, pneumatic or other externally driven device). In some embodiments, the implant comprises a hydrogel (e.g., PVA). In some embodiments, the recess is located within a toe, finger, ankle, knee, shoulder, hip or any other joint.
These and other features, aspects and advantages of the present application are described with reference to drawings of certain embodiments, which are intended to illustrate, but not to limit, the various inventions disclosed herein. It is to be understood that the attached drawings are for the purpose of illustrating concepts and embodiments of the present application and may not be to scale.
The discussion and the figures illustrated and referenced herein describe various embodiments of a cartilage implant, as well as various tools, systems and methods related thereto. A number of these devices and associated treatment methods are particularly well suited to replace deteriorated or otherwise damaged cartilage within a joint. Such implants are configured to remain within the patient's joint on a long-term basis (e.g., for most or all of the life of the patient), and as such, are configured, in some embodiments, to replace native cartilage. Thus, in some embodiments, the implants are configured to be substantially non-biodegradable and/or non-erodable. In some embodiments, for example, an implant is configured to remain within the patient's joint or other portion of the anatomy for a minimum of 20 to 100 years (e.g., about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 years, durations between the foregoing values, etc.) without losing its structural and/or physical properties and/or without losing its ability to function as a cartilage replacement component or device. In other embodiments, the implants are configured to remain within the anatomy for greater than 100 years without losing its structural and/or physical properties and/or without losing its ability to function as a cartilage replacement component. Accordingly, such embodiments can be used to treat osteoarthritis, rheumatoid arthritis, other inflammatory diseases, generalized joint pain and/or other joint diseases. However, the various devices, systems, methods and other features of the embodiments disclosed herein may be utilized or applied to other types of apparatuses, systems, procedures and/or methods, including arrangements that have non-medical benefits or applications.
With continued reference to
According to some embodiments, the base (or bottom) 14 and/or the top 16 of the implant 10 is generally circular. Alternatively, the shape of the ends 14, 16 can be different than circular, such as, for example, oval, square, other rectangular, other polygonal, irregular and/or the like. Further, once securely implanted in a patient's anatomy (e.g., within a recess R), the top 16 of the implant 10 can be generally flush with the adjacent tissue surface. However, in other embodiments, the top 16 of the implant 10 extends above the adjacent tissue T (e.g., as illustrated in
The top and/or bottom surfaces 16, 14 of the implant 10 can be generally flat or planar. In other embodiments, the surface 16, 14 can be non-planar (e.g., curved, domed, convex, concave, fluted, ridged, etc.), as desired or required. The shape of the top and/or bottom surfaces can be selected based on a patient's anatomy, the location within the patient's anatomy in which the implant will be placed and/or one or more other factors or considerations. For example, the implant can be configured to generally or specifically match the slopes, contours and/or other features of the patient's existing cartilaginous and/or bone tissue, the recess and/or the like. Accordingly, the function of a rehabilitated joint or other targeted anatomical region being treated can be improved.
Another embodiment of a tapered implant 110 configured to replace or augment damaged cartilage within a patient is illustrated in
As discussed herein with reference to
With continued reference to
Regardless of its exact size and shape, the base portion can be larger or wider than the top of the implant in order to help ensure that the implant remains securely positioned within a targeted portion of a patient's anatomy (e.g., a joint) following implantation. For example, in some embodiments, the dimension (or area) of the base or bottom of the implant is approximately 10% to 15% (e.g., about 10%, 11%, 12%, 13%, 14%, 15%, ranges between such values, etc.) longer, wider or otherwise larger than the top of the implant. Thus, in embodiments having generally circular bottom and top surfaces, such as, for example, the implant 110 illustrated in
As discussed above with reference to the embodiments illustrated in
With continued reference to
As a result of the shape of the implant and the corresponding implant site (e.g., recess, other opening, etc.), it may be necessary to radially compress the implant (e.g., inwardly, as schematically illustrated by the arrows 20 in
According to some embodiments, radial compression of an implant can affect the implant's overall height, the shape or contours of its outer surfaces (e.g., top or articulating surface, base or bottom surface, sides, etc.) and/or one or more other properties or characteristics of the implant. By way of example, in some embodiments, radial compression of an implant causes the height of the implant to increase (e.g., relative to the height of the implant when it is not radially compressed). Consequently, careful consideration may need to be given to the design of the implant based on, among other things, the expected level of radial compression that may occur once the implant has been properly secured within the implant site. Therefore, the amount of radial compression, and thus its effect on the implant's diameter, height, other dimensions, shape and/or other properties, may need to be carefully determined prior to implantation. Otherwise, upon implantation, an implant may not properly align with adjacent cartilage or other tissue surfaces in a joint or other anatomical location.
According to some embodiments, any of the implant embodiments disclosed herein comprise polyvinyl alcohol (PVA) hydrogels. The implants can comprise one or more other materials, either in addition to or in lieu of PVA, such as, for example, other hydrogels, other polymeric materials, other additives and/or the like. In some embodiments, the PVA content of a hydrogel is approximately 40% by weight. However, the PVA content of an implant can be less or more than about 40% by weight (e.g., approximately 10%, 15%, 20%, 25%, 30%, 32%, 34%, 36%, 37%, 38%, 39%, 41%, 42%, 43%, 44%, 46%, 48%, 50%, 55%, 60%, 65%, 70% by weight, less than about 10% by weight, more than about 70% weight, values between the foregoing ranges, etc.), as desired or required.
Further, the implants can comprise water, saline, other liquids, combinations thereof and/or the like. In some embodiments, the use of saline within a hydrogel implant may be preferred over water, because, under certain circumstances, saline can help maintain osmotic balance with surrounding anatomical tissues following implantation. The exact composition of an implant (e.g., PVA or other hydrogel materials, water, saline or other liquids, other additives, etc.) can be selected so as to provide the resulting implant with the desired or required strength, load bearing capacity, compressibility, flexibility, longevity, durability, resilience, coefficient of friction and/or other properties and characteristics.
In several embodiments, the implants disclosed herein are configured for drug delivery and/or are seeded with growth factors and/or cells. In some embodiments, the implants comprise one or more of the following: chondrocytes, growth factors, bone morphogenetic proteins, collagen, hyaluronic acid, nucleic acids, and stem cells. Such factors and/or any other materials included in the implant and selectively delivered to the implant site can help facilitate and promote the long-term fixation of the implant within the joint or other target area of the anatomy.
In some embodiments, the implants disclosed herein are configured for anchoring during implantation. The implant can comprise one or more anchor sites (which may comprise non-hydrogel portions or tabs) to facilitate anchoring (e.g., suturing, stapling, etc.). In one embodiment, the implant is pre-coupled to one or more anchors. Such anchors can comprise removable and/or permanent fixtures. In some embodiments, the anchors are resorbable or otherwise dissolvable after implantation (e.g., following a particular time period, such as, for instance, 1-30 days, 2-30 weeks, 6-12 months, 1-5 years, greater than 5 years, less than 1 day, etc.). In one embodiment, the implant comprises at least one abrasive surface. In one embodiment, the implant comprises one or more adhesive components. In other embodiments, the tapered shape of the implant permits secure implantation without the need for any anchoring or other fixation. In some embodiments, for any of the implants disclosed herein, one or more implant surfaces can be configured to promote bone adhesion by one or more coatings, substances and/or the like and/or by using an appropriate surface texture along the surface(s). For example, the implant surface can be roughened, can include pores (e.g., superficial pores) and/or any other feature, as desired or required.
In some embodiments, the implants disclosed herein are supported or reinforced by a rigid support frame, such as a ceramic or metallic frame. In some embodiments, the implants disclosed herein are supported or reinforced by a flexible or rigid mesh structure. In other embodiments, the implants do not contain any support or reinforcement structure.
Any of the implant embodiments disclosed herein, or equivalents thereof, can be manufactured using freeze/thaw cycling and/or any other production method. For example, a hydrogel formulation comprising water, saline, PVA (and/or other hydrogel materials), other polymeric materials, other additives and/or the like can be heated and/or otherwise treated as part of a freeze/thaw manufacturing process. In one embodiment, a hydrogel solution comprising saline and about 40% PVA by weight is heated to approximately 121° C. under elevated pressure conditions (e.g., to affect dissolution of the polymer). For example, such a solution can be autoclaved in order to facilitate complete or substantially complete dissolution of the PVA in the saline, water and/or other liquid. Next, the temperature and/or pressure of the solution can be lowered to permit entrapped air and/or other gases to escape. In one embodiment, after the autoclaving or similar step, the solution is generally maintained at a temperature of approximately 95° C. and atmospheric pressure for a predetermined time period.
The solution can then be transferred (e.g., pumped, poured, etc.) into open molds where, once set, will form the desired shape of the implants. One embodiment of such an open mold assembly 200 is illustrated in
With continued reference to
Due in part to the remaining production steps, accommodation of any changes in size (e.g., expansion, contraction, etc.) that may occur or are likely to occur to the implants can be considered during manufacturing by properly sizing and otherwise designing the mold assembly 200. The amount of contraction or expansion of the implants can be based on one or more factors or conditions, such as, for example, the number of freeze/thaw cycles to which the implants are subjected, the temperature and/or pressure ranges associated with the remaining steps and/or the like.
Alternatively, the implants can be formed, at least in part, using an injection molding process and/or any other molding or casting procedure. In such injection or transfer molding techniques, once the hydrogel or other implant solution has been prepared, it can be loaded into an injection cylinder or other container of a molding press. The solution can then be forcibly transferred into a closed mold assembly using a pneumatic or hydraulic ram or any other electromechanical device, system or method. In some embodiments, the hydrogel and/or other solution or implant component is injected into a corresponding closed mold assembly through a standard runner and gate system. Injection molding of implants can provide one or more benefits relative to open mold assemblies. For instance, the devices formed as part of the injection molding techniques typically do not require additional cutting, reshaping, resizing and/or processing, as they are essentially in their final shape immediately after the injection molding step has been completed.
Regardless of how the implants are molded or otherwise shaped or manufactured, they can be subsequently subjected to one or more freeze/thaw cycles, as desired or required. In some embodiments, for example, the implants, while in their respective mold cavities, are cooled using a total of four freeze/thaw cycles wherein the temperature is sequentially varied between approximately −20° C. and 20° C. In other embodiments, however, the number of freeze/thaw cycles, the temperature fluctuation and/or other details related to cooling the implants can be different than disclosed herein, in accordance with a specific production protocol or implant design.
Following freeze/thaw cycling, the implants can be removed from their respective mold cavities and placed in one or more saline and/or other fluid (e.g., other liquid) baths where they can be subjected to additional cooling and/or other treatment procedures (e.g., to further stabilize the physical properties of the implants). According to some embodiments, for instance, the implants undergo an additional eight freeze/thaw cycles while in saline. In other embodiments, such follow-up cooling procedures are either different (e.g., more or fewer freeze/thaw cycles, different type of bath, etc.) or altogether eliminated from the production process, as desired or required.
When the cooling (e.g., freeze/thaw cycling) and/or other treatment steps have been completed, the implants can be inspected to ensure that they do not include any manufacturing flaws or other defects. Further, at least some of the implants can be subjected to selective testing to ensure that they comprise the requisite physical and other characteristics, in accordance with the original design goals and target parameters for the implants. Further, it may be necessary to cut or otherwise process the implants in order to remove any excess portions. In some embodiments, the completed implants are packaged in hermetically sealed plastic trays (or other containers) comprising foil or other types of lids or covering members. A volume of saline and/or other liquid can be included within such trays or other containers to ensure proper hydration of the implants during storage and/or any other steps preceding actual use. In one embodiment, the implant trays or other containers are terminally sterilized using e-beam exposure between about 25 and 40 kGy. Additional details related to producing hydrogel implants can be found in U.S. Pat. Nos. 5,981,826 and 6,231,605, the entireties of both of which are hereby incorporated by reference herein.
According to some embodiments, the overall height (e.g., between the base or bottom surface and the top or articulating surface) of a tapered implant is approximately 10 mm. Further, the diameter or other cross-sectional dimension along or near the top surface of the implant can be about 10 mm. However, in other embodiments, the height, diameter and/or other dimensions of a wedge-type implant can vary, as desired or required. For example, implants adapted for use in larger joints (e.g., knee, shoulder, hip, etc.) can have a height and/or diameter larger than 10 mm (e.g., about 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 18 mm, 20 mm, greater than 20 mm, dimensions between the foregoing values, etc.). Likewise, implants configured for use in smaller joints (e.g., toes) can be smaller than 10 mm in height (e.g., about 2 mm, 4 mm, 6 mm, 8 mm) and/or 10 mm in top diameter (e.g., about 2 mm, 4 mm, 6 mm, 8 mm).
As discussed above with reference to
With continued reference to
According to some embodiments, a drill bit can be cannulated, such that one or more passages or openings 326 extend (e.g., longitudinally) through the device. For example, as illustrated in
As the drill bit 300 is rotated (e.g., either manually or using one or more external driving sources, etc.), sharp edges formed along the distal and/or peripheral portions of the cutters 356 can abrade and remove cartilage, bone and/or other tissue that they engage and contact. In some embodiments, the longitudinal distance D1 (
As the drill bit 300 is rotated and advanced into a targeted region of the patient's anatomy, abraded bone, cartilage and/or other tissue and/or other debris will be created at or near the distal end 330 of the device. Accordingly, in order to permit such debris to be removed from the treatment site, the flange 340 can include one or more openings 344. Thus, abraded materials can stay clear of and not interfere with the working end of the drill bit, allowing the cutters 356 to continue to function normally. Once the distal face 341 of the flange 340 abuts the top surface of the bone being drilled, further advancement of the drill bit 300 can be prevented. This alerts the clinician that the implant site having the desired depth and diameter has been properly created.
With continued reference to the front view of
Accordingly, a drill bit having an articulating cutter or a movable cutting arm can be used to create the necessary taper or slope along the side walls of the recess or opening in a bone or other targeted region of the anatomy. In some embodiments, the articulating cutter is configured to create a curved contour along the bottom and/or side surfaces of the recess. For example, such curved surfaces can include one or more convex and/or concave portions, as desired or required. One embodiment of a drill bit 400 configured to create such a reverse tapered implant site is illustrated in
With continued reference to
According to some embodiments, once the stationary cutters 456 of the drill bit 400 have created a generally cylindrical recess or opening within the patient's targeted bone or other site and the flange 440 contacts a corresponding abutting surface, the surgeon or other clinician can cause the articulating cutter 460 to be deployed outwardly. Thus, the desired reverse taper or wedge shape can be created along the sides of the implant site. As shown in
In some embodiments, once released outwardly (e.g., by retraction of the sleeve 470), the articulating cutter 460 can assume a fully extended orientation in order to create the necessary taper to the adjacent side walls of the implant site. Thus, a sufficiently strong biasing or other type of force can be imparted on the articulating cutter 460 to ensure that it can reach the targeted fully deployed position. The articulating cutter 460 can be biased radially outwardly using a spring or other resilient member. Alternatively, any other force imparting device or method can be used to ensure that the articulating cutter 460 fully extends when selectively deployed by the clinician. Once the necessary taper along the sides of the implant site has been created, the sleeve 470 can be returned to its original orientation (e.g., closer to the flange 440, as illustrated in
According to some embodiments, the sleeve 470 is normally resiliently biased in the distal position (e.g., as illustrated in
In other embodiments, a reverse tapered recess can be created using a two or multi-step process. For example, as part of an initial step, a first drill bit can be used to create a generally cylindrical opening within a targeted bone. One embodiment of a drill bit that is configured to only create a generally cylindrical opening is illustrated and discussed herein with reference to
With reference to
According to some embodiments, the drill bit can be advanced to the targeted drill site of the patient bone or other anatomical location with the assistance of a guide pin. As discussed herein, any one of the drill bit arrangements disclosed herein can include a longitudinal lumen or other passage. Thus, a guide pin can be tamped at least partially into the surface of the bone to be drilled. The guide pin may be advanced through the patient's anatomy using a trocar or similar device. Next, a cannulated drill bit, as discussed herein, can be passed over the guide pin to ensure that the distal, working end of the drill bit is properly positioned relative to the treatment site (e.g., joint).
Once a reverse taper implant site has been created in the targeted joint or other portion of the patient (and, where applicable, the guide pin or other member has been removed), a clinician can deliver the implant to the implant site using an introducer 600. As illustrated in
The neck portion 608 of the introducer tube 610 can be positioned at least partially within the opening or recess into which the implant will be secured. In some embodiments, the introducer can be sized, shaped and otherwise configured to that the neck portion 608 fits generally snugly within the implant site. With reference to
As the implant 10 is urged deeper (e.g., more distally) into the interior of the introducer 600, the implant 10 may become radially compressed by the adjacent interior walls. If sufficient force is applied to the implant 10, the implant 10 passes through the neck portion 608 of the introducer and into the implant site R. As illustrated in
According to some embodiments, once a reverse taper site has been created in the targeted joint or other portion of the patient (and, where applicable, the guide pin or other member has been removed), a clinician can deliver the implant to the implant site using a mechanically-assisted delivery tool or introducer 800. One embodiment of such a tool is illustrated in
Such mechanically-assisted delivery devices can be helpful in advancing the implant through the interior of an introducer tube against a relatively large resistance of back-pressure. Such a resistive force can be particularly high when the implant comprises a relatively large taper angle θ. Accordingly, in some embodiments, the use of such delivery tools makes the delivery of reverse taper implants into corresponding implant sites possible, while allowing the clinician to safely and accurately guide the implant into a targeted anatomical implant site. In several embodiments, the delivery tool is capable of overcoming resistive forces of about 5 to about 20 pounds. In some embodiments, the delivery tool exerts a force about 5 to about 25. In some embodiments, the delivery device is operated by or with the assistance of one or more motors. For example, in some embodiments, the clamp is moved (e.g., rotated) relative to the handle using (or with the assistance of) one or more stepper motors and/or any other type of motor or actuator. In some embodiments, delivery of an implant through the introducer tube 810 is accomplished with at least some assistance from air or pneumatic pressure. For example, air or other fluid can be injected into the interior of the introducer tube once the implant is inserted therein. The delivery of air can be incorporated into a plunger member 820 (e.g., via one or more interior lumens) so that the implant can be advanced through the introducer tube 810 into the implant site using mechanical force (e.g., by moving the plunger 820 through the tube 810) and/or by injecting air and/or other fluids into the interior of the tube 810. The fluid openings through the plunger 820 and/or any other fluid passages can be placed in fluid communication with a compressor or other fluid generating device. Advancement of the implant through the introducer tube 810 can be accomplished by applying a vacuum along or near the distal end of the tube 810 (e.g., through one or more vacuum ports along the introducer tube 810). Such vacuum ports or openings can be placed in fluid communication with a vacuum or other suction generating device.
According to some embodiments, the delivery tool comprises one or more depth stop features or components to ensure that the implant being delivered to a target implant site is properly delivered into the target implant site. In some embodiments, the depth stop features help protect the structural integrity of the implant as the implant is being inserted within the target anatomical implant site.
In some embodiments, the delivery device comprises and/or is operatively coupled to one or more pressure gauges or other pressure or force measuring devices, members or features. Such gauges or other measurement devices can help ensure that a maximum backpressure or force is not exceeded when operating the device. This can help protect the integrity of the implant (e.g., to ensure that the structural integrity, water composition and/or other properties of the implant are maintained), protect the delivery device, protect the user and/or the patient and/or provide one or more other advantages or benefits.
According to some embodiments, the introducer tube 810 of the delivery tool or device 800 comprises one or more viewing windows that permit the implant to be viewed as it is being advanced through the device 800 to the implant site. In some embodiments, the introducer tube 800 (and thus the longitudinal axis along which the implant is advanced through the delivery tool or device) is substantially perpendicular with the surface of the bone or other anatomical site into which the implant will be delivered and/or the handle 830 of the device 800.
According to some embodiments, at least a portion of the interior of the introducer tube 810 comprises and/or is otherwise coated or lined with one or more absorbable or lubricious layers, materials and/or other substances. Such materials can help preserve the moisture level of the implant as it is being advanced through the introducer tube 810. The interior surface of the introducer tube can comprise a low coefficient of friction to facilitate the delivery of an implant through the delivery device or tool 800. In some embodiments, the effective coefficient of friction along the interior of the introducer tube can be lowered polishing such surfaces. As noted herein, the introducer, including its interior surfaces, can comprise surgical grade stainless steel.
According to some embodiments, the delivery tool or device 800 is incorporated into the drill bit configured to create a reverse tapered implant site. For example, such a combination device can be coupled to a drill or other mechanical device to first create the implant site. Then, the combination device can take advantage of the mechanical output generated by the drill and/or other mechanical or motorized device to help urge the implant through the introducer tube of the combination device.
As illustrated in
As best illustrated in the longitudinal cross-sectional view of
According to some embodiments, the proximal portion 812 of the introducer tube 810 includes one or more slits or other openings 818. As shown, such a slit 818 can begin adjacent to or near the externally threaded portion 814 of the tube 810 and can extend to or near the proximal end 802 of the tube 810. In some embodiments, the proximal portion 812 of the introducer tube includes two (or more) slits 818 located opposite each other in the introducer 810 to form a channel through the proximal portion 812. In some embodiments, for example as shown in
With reference to
With continued reference to
According to some embodiments, as illustrated in
With continued reference to the perspective view of the handle illustrated in
As shown in
In some embodiments, the elongate proximal section or portion 832 of the handle comprises a grasping portion 838 configured to be selectively gripped and manipulated by a user during use. The grasping portion 838 can be contoured, shaped and/or otherwise configured to improve the user's grip on the handle 830. In the illustrated embodiment, the distal section or portion 836 of the handle comprises a generally rectangular cross-section. However, the distal portion and/or any other portion of the handle 830 can include any other shape (e.g., circular, oval, square, polygonal, etc.). When the nut portion of introducer receiving portion 834 is oriented horizontally, the distal section 836 of the handle comprises a generally vertical shape so that it is taller than it is deep.
According to some embodiments, the distal section 836 of the handle 830 comprises a keyhole 837 or other opening for coupling to the clamp 840 of the device. The keyhole 837 or other opening can be configured to allow the clamp 840 to be quickly and easily connected to and/or disconnected from the handle 830. In other arrangements, however, the clamp 840 can be permanently or substantially permanently attached to the handle 830. In other embodiments, the size, shape, orientation, and/or other details or properties of the handle 830 can be different than shown in
With reference to
Therefore, the handle 830 and the clamp 840 can be connected to one another about a hinge or other rotatable point, thereby permitting the handle to be selectively rotated and/or otherwise moved relative to the clamp. As discussed in greater detail herein, such a relative rotation between the clamp and the handle can be used to provide the mechanical force necessary to move the plunger 820 within the introducer tube 810. This can advantageously urge an implant (e.g., tapered hydrogel implant) through the tube 810 and into a target recess of an implant site. Accordingly, the forces created by moving the clamp relative to the handle can help move an implant against relatively high back-forces (e.g., against relatively high friction and/or other resistive forces) within the introducer tube. Such movement of the implant can be particularly difficult for reverse tapered implants where at least a portion of such implants experiences generally high radially compressive forces while being moved through an interior lumen or other opening of the introducer tube 810.
According to some embodiments, to assemble the delivery device 800 in preparation for use, the user inserts the implant 10 (e.g., reverse tapered implant, other joint implant, etc.) into the introducer tube 810 via the proximal end 802. The plunger 820 can then be inserted into the proximal end 802 of the introducer tube 810 and used to distally advance the implant 10 within the introducer tube 810. Once the handle 830 is coupled to the introducer tube 810 (e.g., by threading the nut portion or introducer tube receiving portion 834 onto the externally threaded portion 814 of the introducer tube 810), the clamp 840 can be coupled to the handle 830 by inserting the key 847 (or other protruding portion or feature) of the clamp 840 into the keyhole 837 (or other opening) of the handle 830. When assembled, e.g., as illustrated in
As discussed in greater detail herein, the clamp 840 can be rotatably attached to the handle 830 (e.g., at a hinge point), thereby allowing a user to selectively rotate or otherwise move the clamp relative to the handle (e.g., to move the clamp 840 toward or away from the handle 830 within the slit, groove or other opening of the introducer tube 810). In some embodiments, an offset between the distal section 836 and proximal section 832 of the handle 830 permits the distal portion 846 of the clamp 840 to be aligned with the slit 818 in the introducer tube so that the clamp can be selectively moved within the slit 818 when the clamp 840 and handle 830 are coupled to one another (e.g., via the key 847-keyhole 837 joint or a similar feature or mechanism). Therefore, in some embodiments, the delivery device 800 is configured for quick, easy and convenient assembly and disassembly for cleaning, sterilization, repair, maintenance and/or any other reason or purpose.
According to some embodiments, the various components of the mechanically-assisted delivery device 800 comprise one or more rigid and/or semi-rigid materials that are configured to withstand the forces, moments, chemicals and/or other substances, temperature fluctuations and/or other elements to which they may be exposed. For example, the components of the implant delivery device can comprise one or more metals (e.g., stainless steel, other surgical steel, other types of steel, etc.), alloys, plastics and/or the like. Such materials can permit the device to be autoclaved, sterilized or otherwise cleaned during a specific disinfection protocol. In addition, the structural and other physical characteristics of the device can permit the user to exert the necessary forces using the device to deliver implants of various sizes, shapes and/or configurations through the corresponding introducer tube and into a target implant site of a patient.
In use, the distal neck portion 806 of the introducer tube 810 can be positioned at least partially within the opening, recess or other implant site into which the implant 10 will be secured. In some embodiments, the introducer tube 810 is sized, shaped and otherwise configured to that the neck portion 806 fits generally snugly within the implant site. To deliver the implant 10 (e.g., reverse taper implant) through the device 800 and into the targeted implant site, the user can urge the clamp 840 toward the handle 830 of the device (e.g., so that the clamp rotates or otherwise moves relative to the handle). According to some embodiments, as the distal portion 846 of the clamp 840 moves downwardly through the slit, slot or other opening 818 of the introducer tube 810, a portion of the clamp 840 (e.g., the distal portion 846) contacts the plunger 820 (e.g., the domed proximal end 824), and urges the plunger 820 distally within the introducer tube 810.
As illustrated in
Accordingly, the mechanically-assisted delivery devices disclosed herein, or equivalents thereof, can facilitate the compression and delivery of reverse tapered implants within a target implant site. In some embodiments, the mechanically-assisted delivery device can be configured to be operated at least partially with the assistance of a mechanical motor, a pneumatic device and/or another external device. For example, the clamp of the device can be moved relative to the handle by or with the assistance of one or more motors (e.g., regulated by a user using a button, knob, dial and/or other controller). Such embodiments can further facilitate the delivery of implants within an implant site of a patient.
To assist in the description of the disclosed embodiments, words such as upward, upper, bottom, downward, lower, rear, front, vertical, horizontal, upstream, downstream have been used above to describe different embodiments and/or the accompanying figures. It will be appreciated, however, that the different embodiments, whether illustrated or not, can be located and oriented in a variety of desired positions.
Although several embodiments and examples are disclosed herein, the present application extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the inventions and modifications and equivalents thereof. It is also contemplated that various combinations or subcombinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the inventions. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combine with or substituted for one another in order to form varying modes of the disclosed inventions. Thus, it is intended that the scope of the present inventions herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.
This application is a continuation application of U.S. patent application Ser. No. 16/453,020, filed Jun. 26, 2019, which is a divisional application of U.S. patent application Ser. No. 15/386,756, now U.S. Pat. No. 10,376,368, which is a continuation application of U.S. patent application Ser. No. 14/826,918, filed Aug. 14, 2015, now U.S. Pat. No. 9,526,632, which is a continuation application of U.S. patent application Ser. No. 13/480,272, filed May 24, 2012, now a U.S. Pat. No. 9,155,543, which claims priority benefit of U.S. Provisional Application No. 61/490,507, filed May 26, 2011, the entireties of all of which are hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3276996 | Lazare | Oct 1966 | A |
3663470 | Nishimura et al. | May 1972 | A |
3673612 | Merrill et al. | Jul 1972 | A |
3849238 | Gould et al. | Nov 1974 | A |
3859421 | Hucke | Jan 1975 | A |
4083906 | Schindler et al. | Apr 1978 | A |
4158684 | Klawitter et al. | Jun 1979 | A |
4205400 | Shen et al. | Jun 1980 | A |
4351069 | Ballintyn et al. | Sep 1982 | A |
4472542 | Nambu | Sep 1984 | A |
4517295 | Bracke et al. | May 1985 | A |
4524064 | Nambu | Jun 1985 | A |
4609337 | Wichterle et al. | Sep 1986 | A |
4663358 | Hyon et al. | May 1987 | A |
4664857 | Nambu | May 1987 | A |
4693939 | Ofstead | Sep 1987 | A |
4731081 | Tiffany et al. | Mar 1988 | A |
4734097 | Tanabe et al. | Mar 1988 | A |
4738255 | Goble et al. | Apr 1988 | A |
4753761 | Suzuki | Jun 1988 | A |
4759766 | Buttner-Janz et al. | Jul 1988 | A |
4772284 | Suzuki | Sep 1988 | A |
4784990 | Nimrod et al. | Nov 1988 | A |
4787905 | Loi | Nov 1988 | A |
4808353 | Nambu et al. | Feb 1989 | A |
4828493 | Nambu et al. | May 1989 | A |
4851168 | Graiver et al. | Jul 1989 | A |
4911720 | Collier | Mar 1990 | A |
4916170 | Nambu | Apr 1990 | A |
4946461 | Fischer et al. | Aug 1990 | A |
4988761 | Ikada et al. | Jan 1991 | A |
4995882 | Destouet et al. | Feb 1991 | A |
5047055 | Bao et al. | Sep 1991 | A |
5080674 | Jacobs et al. | Jan 1992 | A |
5095037 | Iwamitsu et al. | Mar 1992 | A |
5106743 | Franzblau et al. | Apr 1992 | A |
5106876 | Kawamura | Apr 1992 | A |
5108428 | Capecchi et al. | Apr 1992 | A |
5108436 | Chu et al. | Apr 1992 | A |
5118667 | Adams et al. | Jun 1992 | A |
5141973 | Kobayashi et al. | Aug 1992 | A |
5171322 | Kenny | Dec 1992 | A |
5171574 | Kuberasampath et al. | Dec 1992 | A |
5192326 | Bao et al. | Mar 1993 | A |
5206023 | Hunziker | Apr 1993 | A |
5219360 | Georgiade | Jun 1993 | A |
5234456 | Silvestrini | Aug 1993 | A |
5244799 | Anderson | Sep 1993 | A |
5258023 | Reger | Nov 1993 | A |
5258042 | Mehta | Nov 1993 | A |
5258043 | Stone | Nov 1993 | A |
5260066 | Wood et al. | Nov 1993 | A |
5287857 | Mann | Feb 1994 | A |
5288503 | Wood et al. | Feb 1994 | A |
5290494 | Coombes et al. | Mar 1994 | A |
5314477 | Marnay | May 1994 | A |
5314478 | Oka et al. | May 1994 | A |
5326364 | Clift, Jr. et al. | Jul 1994 | A |
5336551 | Gravier et al. | Aug 1994 | A |
5336767 | Della Valle et al. | Aug 1994 | A |
5343877 | Park | Sep 1994 | A |
5344459 | Swartz | Sep 1994 | A |
5346935 | Suzuki et al. | Sep 1994 | A |
5397572 | Coombes et al. | Mar 1995 | A |
5399591 | Smith et al. | Mar 1995 | A |
5401269 | Buttner-Janz et al. | Mar 1995 | A |
5409904 | Hecht et al. | Apr 1995 | A |
5410016 | Hubbell et al. | Apr 1995 | A |
5442053 | Della Valle et al. | Aug 1995 | A |
5458643 | Oka et al. | Oct 1995 | A |
5458645 | Bertin | Oct 1995 | A |
5486197 | Le et al. | Jan 1996 | A |
5489310 | Mikhail | Feb 1996 | A |
5490962 | Cima et al. | Feb 1996 | A |
5492697 | Boyan et al. | Feb 1996 | A |
5494940 | Unger et al. | Feb 1996 | A |
5502082 | Unger et al. | Mar 1996 | A |
5512475 | Naughton et al. | Apr 1996 | A |
5522898 | Bao | Jun 1996 | A |
5534028 | Bao et al. | Jul 1996 | A |
5541234 | Unger et al. | Jul 1996 | A |
5545229 | Parsons et al. | Aug 1996 | A |
5556429 | Felt | Sep 1996 | A |
5556431 | Buttner-Janz | Sep 1996 | A |
5578217 | Unger et al. | Nov 1996 | A |
5601562 | Wolf et al. | Feb 1997 | A |
5626861 | Laurencin et al. | May 1997 | A |
5645592 | Nicolais et al. | Jul 1997 | A |
5656450 | Boyan et al. | Aug 1997 | A |
5658329 | Purkait | Aug 1997 | A |
5674241 | Bley et al. | Oct 1997 | A |
5674295 | Ray et al. | Oct 1997 | A |
5674296 | Bryan et al. | Oct 1997 | A |
5688459 | Mao et al. | Nov 1997 | A |
5700289 | Breitbart et al. | Dec 1997 | A |
5705780 | Bao | Jan 1998 | A |
5716416 | Lin | Feb 1998 | A |
5750585 | Park et al. | May 1998 | A |
5766618 | Laurencin et al. | Jun 1998 | A |
5769897 | Harle | Jun 1998 | A |
5769899 | Schwartz et al. | Jun 1998 | A |
5789464 | Muller | Aug 1998 | A |
5795353 | Felt | Aug 1998 | A |
5824093 | Ray et al. | Oct 1998 | A |
5824094 | Serhan et al. | Oct 1998 | A |
5844016 | Sawhney et al. | Dec 1998 | A |
5847046 | Jiang et al. | Dec 1998 | A |
5855610 | Vacanti et al. | Jan 1999 | A |
5863297 | Walter et al. | Jan 1999 | A |
5863551 | Woerly | Jan 1999 | A |
5876452 | Anthanasiou et al. | Mar 1999 | A |
5876741 | Ron | Mar 1999 | A |
5880216 | Tanihara et al. | Mar 1999 | A |
5882351 | Fox | Mar 1999 | A |
5900245 | Sawhney et al. | May 1999 | A |
5916585 | Cook et al. | Jun 1999 | A |
5925626 | Della Valle et al. | Jul 1999 | A |
5928239 | Mirza | Jul 1999 | A |
5935129 | McDevitt et al. | Aug 1999 | A |
5944754 | Vacanti | Aug 1999 | A |
5947844 | Shimosaka et al. | Sep 1999 | A |
5948829 | Wallajapet et al. | Sep 1999 | A |
5957787 | Hwang | Sep 1999 | A |
5976186 | Bao et al. | Nov 1999 | A |
5981826 | Ku et al. | Nov 1999 | A |
6001352 | Boyan et al. | Dec 1999 | A |
6027744 | Vacanti et al. | Feb 2000 | A |
6060534 | Ronan et al. | May 2000 | A |
6093205 | McLeod et al. | Jul 2000 | A |
6102954 | Albrektsson et al. | Aug 2000 | A |
6103255 | Levene et al. | Aug 2000 | A |
6132465 | Ray et al. | Oct 2000 | A |
6156067 | Bryan et al. | Dec 2000 | A |
6171610 | Vacanti et al. | Jan 2001 | B1 |
6187329 | Agrawal et al. | Feb 2001 | B1 |
6206927 | Fell | Mar 2001 | B1 |
6224630 | Bao et al. | May 2001 | B1 |
6231605 | Ku | May 2001 | B1 |
6245026 | Campbell | Jun 2001 | B1 |
6255359 | Agrawal et al. | Jul 2001 | B1 |
6264695 | Stoy | Jul 2001 | B1 |
6268405 | Yao et al. | Jul 2001 | B1 |
6271278 | Park et al. | Aug 2001 | B1 |
6280475 | Bao et al. | Aug 2001 | B1 |
6334044 | Wasai et al. | Dec 2001 | B1 |
6337198 | Levene et al. | Jan 2002 | B1 |
6340369 | Ferree | Jan 2002 | B1 |
6341952 | Gaylo et al. | Jan 2002 | B2 |
6344058 | Ferree | Feb 2002 | B1 |
6355699 | Vyakarnam et al. | Mar 2002 | B1 |
6358251 | Mirza | Mar 2002 | B1 |
6371984 | Van Dyke et al. | Apr 2002 | B1 |
6376573 | White et al. | Apr 2002 | B1 |
6379962 | Holy et al. | Apr 2002 | B1 |
6383519 | Sapieszko et al. | May 2002 | B1 |
6402784 | Wardlaw | Jun 2002 | B1 |
6402785 | Zdeblick et al. | Jun 2002 | B1 |
6419704 | Ferree | Jul 2002 | B1 |
6428576 | Haldimann | Aug 2002 | B1 |
6451059 | Janas et al. | Sep 2002 | B1 |
6472210 | Holy et al. | Oct 2002 | B1 |
6482234 | Weber et al. | Nov 2002 | B1 |
6531523 | Davankov et al. | Mar 2003 | B1 |
6533818 | Weber et al. | Mar 2003 | B1 |
6534084 | Vyakarnam et al. | Mar 2003 | B1 |
6558421 | Fell et al. | May 2003 | B1 |
6602291 | Ray et al. | Aug 2003 | B1 |
6607558 | Kuras | Aug 2003 | B2 |
6610094 | Husson | Aug 2003 | B2 |
6629997 | Mansmann | Oct 2003 | B2 |
6645248 | Casutt | Nov 2003 | B2 |
6667049 | Janas et al. | Dec 2003 | B2 |
6679917 | Ek | Jan 2004 | B2 |
6686437 | Buchman et al. | Feb 2004 | B2 |
6707558 | Bennett | Mar 2004 | B2 |
6710126 | Hirt et al. | Mar 2004 | B1 |
6726721 | Stoy et al. | Apr 2004 | B2 |
6733533 | Lozier | May 2004 | B1 |
6734000 | Chin et al. | May 2004 | B2 |
6740118 | Eisermann et al. | May 2004 | B2 |
6773713 | Bonassar et al. | Aug 2004 | B2 |
6783546 | Zucherman et al. | Aug 2004 | B2 |
6783721 | Higham et al. | Aug 2004 | B2 |
6800298 | Burdick et al. | Oct 2004 | B1 |
6802863 | Lawson et al. | Oct 2004 | B2 |
6827743 | Eisermann et al. | Dec 2004 | B2 |
6840960 | Bubb | Jan 2005 | B2 |
6849092 | Van Dyke et al. | Feb 2005 | B2 |
6855743 | Gvozdic | Feb 2005 | B1 |
6875232 | Nigam | Apr 2005 | B2 |
6875386 | Ward et al. | Apr 2005 | B1 |
6875442 | Holy et al. | Apr 2005 | B2 |
6878384 | Cruise et al. | Apr 2005 | B2 |
6881228 | Zdeblick et al. | Apr 2005 | B2 |
6893463 | Fell | May 2005 | B2 |
6893466 | Trieu | May 2005 | B2 |
6923811 | Carl et al. | Aug 2005 | B1 |
6960617 | Omidian et al. | Nov 2005 | B2 |
6982298 | Calabro et al. | Jan 2006 | B2 |
6993406 | Cesarano, III et al. | Jan 2006 | B1 |
7008635 | Coury et al. | Mar 2006 | B1 |
7012034 | Heide et al. | Mar 2006 | B2 |
7022522 | Guan et al. | Apr 2006 | B2 |
7029479 | Tallarida et al. | Apr 2006 | B2 |
7048766 | Ferree | May 2006 | B2 |
7052515 | Simonson | May 2006 | B2 |
7060097 | Fraser et al. | Jun 2006 | B2 |
7066958 | Ferree | Jun 2006 | B2 |
7066960 | Dickman | Jun 2006 | B1 |
7083649 | Zucherman et al. | Aug 2006 | B2 |
7091191 | Laredo et al. | Aug 2006 | B2 |
7156877 | Lotz et al. | Jan 2007 | B2 |
7186419 | Petersen | Mar 2007 | B2 |
7201774 | Ferree | Apr 2007 | B2 |
7201776 | Ferree et al. | Apr 2007 | B2 |
7214245 | Marcolongo et al. | May 2007 | B1 |
7217294 | Kusanagi et al. | May 2007 | B2 |
7235592 | Muratoglu et al. | Jun 2007 | B2 |
7250060 | Trieu | Jul 2007 | B2 |
7258692 | Thelen et al. | Aug 2007 | B2 |
7264634 | Schmieding | Sep 2007 | B2 |
7282165 | Williams, III et al. | Oct 2007 | B2 |
7291169 | Hodorek | Nov 2007 | B2 |
7316919 | Childs et al. | Jan 2008 | B2 |
7332117 | Higham et al. | Feb 2008 | B2 |
7357798 | Sharps et al. | Apr 2008 | B2 |
7377942 | Berry | May 2008 | B2 |
7682540 | Boyan et al. | Mar 2010 | B2 |
7731988 | Thomas et al. | Jun 2010 | B2 |
7745532 | Ruberti et al. | Jun 2010 | B2 |
7828853 | Ek et al. | Nov 2010 | B2 |
7910124 | Boyan et al. | Mar 2011 | B2 |
7985781 | Muratoglu et al. | Jul 2011 | B2 |
8002830 | Boyan et al. | Aug 2011 | B2 |
8142808 | Boyan et al. | Mar 2012 | B2 |
8318192 | Boyan et al. | Nov 2012 | B2 |
8334044 | Myung et al. | Dec 2012 | B2 |
8475503 | Deoziere et al. | Jul 2013 | B2 |
8486436 | Boyan et al. | Jul 2013 | B2 |
8709045 | Folsom | Apr 2014 | B1 |
8895073 | Boyan et al. | Nov 2014 | B2 |
9155543 | Walsh et al. | Oct 2015 | B2 |
9526632 | Walsh et al. | Dec 2016 | B2 |
9545310 | Maher et al. | Jan 2017 | B2 |
9737294 | Wales et al. | Aug 2017 | B2 |
9907663 | Patrick et al. | Mar 2018 | B2 |
10350072 | Axelrod et al. | Jul 2019 | B2 |
10376368 | Walsh et al. | Aug 2019 | B2 |
20010016741 | Burkus et al. | Aug 2001 | A1 |
20010029399 | Ku | Oct 2001 | A1 |
20010038831 | Park et al. | Nov 2001 | A1 |
20010039455 | Simon et al. | Nov 2001 | A1 |
20010046488 | Vandenburgh et al. | Nov 2001 | A1 |
20020026244 | Trieu | Feb 2002 | A1 |
20020031500 | Maclaughlin et al. | Mar 2002 | A1 |
20020034646 | Canham | Mar 2002 | A1 |
20020072116 | Bhatia et al. | Jun 2002 | A1 |
20020140137 | Sapieszko et al. | Oct 2002 | A1 |
20020173855 | Mansmann | Nov 2002 | A1 |
20020183845 | Mansmann | Dec 2002 | A1 |
20020183848 | Ray et al. | Dec 2002 | A1 |
20020187182 | Kramer et al. | Dec 2002 | A1 |
20030008395 | Holy et al. | Jan 2003 | A1 |
20030008396 | Ku | Jan 2003 | A1 |
20030021823 | Landers et al. | Jan 2003 | A1 |
20030055505 | Sicotte et al. | Mar 2003 | A1 |
20030059463 | Lahtinen | Mar 2003 | A1 |
20030082808 | Guan et al. | May 2003 | A1 |
20030175656 | Livne et al. | Sep 2003 | A1 |
20030176922 | Lawson et al. | Sep 2003 | A1 |
20030199984 | Trieu | Oct 2003 | A1 |
20030220695 | Sevrain | Nov 2003 | A1 |
20030233150 | Bourne et al. | Dec 2003 | A1 |
20030236573 | Evans et al. | Dec 2003 | A1 |
20040010048 | Evans et al. | Jan 2004 | A1 |
20040024465 | Lambrecht et al. | Feb 2004 | A1 |
20040034434 | Evans et al. | Feb 2004 | A1 |
20040044412 | Lambrecht et al. | Mar 2004 | A1 |
20040052867 | Canham | Mar 2004 | A1 |
20040059415 | Schmieding | Mar 2004 | A1 |
20040059425 | Schmieding | Mar 2004 | A1 |
20040063200 | Chaikof et al. | Apr 2004 | A1 |
20040064195 | Herr | Apr 2004 | A1 |
20040073312 | Eisermann et al. | Apr 2004 | A1 |
20040092653 | Ruberti et al. | May 2004 | A1 |
20040117022 | Marnay et al. | Jun 2004 | A1 |
20040143327 | Ku | Jul 2004 | A1 |
20040143329 | Ku | Jul 2004 | A1 |
20040143333 | Bain et al. | Jul 2004 | A1 |
20040147016 | Rowley et al. | Jul 2004 | A1 |
20040171143 | Chin et al. | Sep 2004 | A1 |
20040172135 | Mitchell | Sep 2004 | A1 |
20040220296 | Lowman et al. | Nov 2004 | A1 |
20040220669 | Studer | Nov 2004 | A1 |
20040220670 | Eisermann et al. | Nov 2004 | A1 |
20040249465 | Ferree | Dec 2004 | A1 |
20050037052 | Udipi et al. | Feb 2005 | A1 |
20050043733 | Eisermann et al. | Feb 2005 | A1 |
20050043802 | Eisermann et al. | Feb 2005 | A1 |
20050049706 | Brodke et al. | Mar 2005 | A1 |
20050055094 | Kuslich | Mar 2005 | A1 |
20050055099 | Ku | Mar 2005 | A1 |
20050071003 | Ku | Mar 2005 | A1 |
20050074877 | Mao | Apr 2005 | A1 |
20050079200 | Rathenow et al. | Apr 2005 | A1 |
20050090901 | Studer | Apr 2005 | A1 |
20050096744 | Trieu et al. | May 2005 | A1 |
20050106255 | Ku | May 2005 | A1 |
20050137677 | Rush | Jun 2005 | A1 |
20050137707 | Malek | Jun 2005 | A1 |
20050143826 | Zucherman et al. | Jun 2005 | A1 |
20050149196 | Zucherman et al. | Jul 2005 | A1 |
20050154462 | Zucherman et al. | Jul 2005 | A1 |
20050154463 | Trieu | Jul 2005 | A1 |
20050169963 | Van Dyke et al. | Aug 2005 | A1 |
20050171608 | Peterman et al. | Aug 2005 | A1 |
20050177238 | Khandkar et al. | Aug 2005 | A1 |
20050209704 | Maspero et al. | Sep 2005 | A1 |
20050216087 | Zucherman et al. | Sep 2005 | A1 |
20050228500 | Kim et al. | Oct 2005 | A1 |
20050233454 | Nies et al. | Oct 2005 | A1 |
20050244449 | Sayer et al. | Nov 2005 | A1 |
20050260178 | Vandenburgh et al. | Nov 2005 | A1 |
20050261682 | Ferree | Nov 2005 | A1 |
20050273176 | Ely et al. | Dec 2005 | A1 |
20050277921 | Eisermann et al. | Dec 2005 | A1 |
20050278025 | Ku et al. | Dec 2005 | A1 |
20050287187 | Mansmann | Dec 2005 | A1 |
20060002890 | Hersel et al. | Jan 2006 | A1 |
20060052874 | Johnson et al. | Mar 2006 | A1 |
20060052875 | Bernero et al. | Mar 2006 | A1 |
20060052878 | Schmieding | Mar 2006 | A1 |
20060058413 | Leistner et al. | Mar 2006 | A1 |
20060064172 | Trieu | Mar 2006 | A1 |
20060064173 | Guederian | Mar 2006 | A1 |
20060083728 | Kusanagi et al. | Apr 2006 | A1 |
20060100304 | Vresilovic et al. | May 2006 | A1 |
20060121609 | Yannas et al. | Jun 2006 | A1 |
20060122706 | Lo | Jun 2006 | A1 |
20060136064 | Sherman | Jun 2006 | A1 |
20060136065 | Gontarz et al. | Jun 2006 | A1 |
20060178748 | Dinger, III et al. | Aug 2006 | A1 |
20060200250 | Ku | Sep 2006 | A1 |
20060206209 | Cragg et al. | Sep 2006 | A1 |
20060224244 | Thomas et al. | Oct 2006 | A1 |
20060229721 | Ku | Oct 2006 | A1 |
20060235541 | Hodorek | Oct 2006 | A1 |
20060241777 | Partin et al. | Oct 2006 | A1 |
20060257560 | Barone et al. | Nov 2006 | A1 |
20060259144 | Trieu | Nov 2006 | A1 |
20060282165 | Pisharodi | Dec 2006 | A1 |
20060282166 | Molz et al. | Dec 2006 | A1 |
20060287730 | Segal et al. | Dec 2006 | A1 |
20060293561 | Abay | Dec 2006 | A1 |
20060293751 | Lotz et al. | Dec 2006 | A1 |
20070010889 | Francis | Jan 2007 | A1 |
20070014867 | Kusanagi et al. | Jan 2007 | A1 |
20070032873 | Pisharodi | Feb 2007 | A1 |
20070038301 | Hudgins | Feb 2007 | A1 |
20070043441 | Pisharodi | Feb 2007 | A1 |
20070067036 | Hudgins et al. | Mar 2007 | A1 |
20070073402 | Vresilovic et al. | Mar 2007 | A1 |
20070093906 | Hudgins et al. | Apr 2007 | A1 |
20070106387 | Marcolongo et al. | May 2007 | A1 |
20070116678 | Sung et al. | May 2007 | A1 |
20070118218 | Hooper | May 2007 | A1 |
20070118225 | Hestad et al. | May 2007 | A1 |
20070134333 | Thomas et al. | Jun 2007 | A1 |
20070135922 | Trieu | Jun 2007 | A1 |
20070142326 | Shue | Jun 2007 | A1 |
20070162135 | Segal et al. | Jul 2007 | A1 |
20070164464 | Ku | Jul 2007 | A1 |
20070167541 | Ruberti et al. | Jul 2007 | A1 |
20070168039 | Trieu | Jul 2007 | A1 |
20070173951 | Wijlaars et al. | Jul 2007 | A1 |
20070179606 | Huyghe et al. | Aug 2007 | A1 |
20070179614 | Heinz et al. | Aug 2007 | A1 |
20070179615 | Heinz et al. | Aug 2007 | A1 |
20070179617 | Brown et al. | Aug 2007 | A1 |
20070179618 | Trieu et al. | Aug 2007 | A1 |
20070179620 | Seaton et al. | Aug 2007 | A1 |
20070179621 | McClellan, III et al. | Aug 2007 | A1 |
20070179622 | Denoziere et al. | Aug 2007 | A1 |
20070196454 | Stockman et al. | Aug 2007 | A1 |
20070202074 | Shalaby | Aug 2007 | A1 |
20070203095 | Sadozai et al. | Aug 2007 | A1 |
20070203580 | Yeh | Aug 2007 | A1 |
20070208426 | Trieu | Sep 2007 | A1 |
20070213718 | Trieu | Sep 2007 | A1 |
20070213822 | Trieu | Sep 2007 | A1 |
20070213823 | Trieu | Sep 2007 | A1 |
20070213824 | Trieu | Sep 2007 | A1 |
20070213825 | Thramann | Sep 2007 | A1 |
20070224238 | Mansmann et al. | Sep 2007 | A1 |
20070225823 | Hawkins et al. | Sep 2007 | A1 |
20070227547 | Trieu | Oct 2007 | A1 |
20070233135 | Gil et al. | Oct 2007 | A1 |
20070233259 | Muhanna et al. | Oct 2007 | A1 |
20070265626 | Seme | Nov 2007 | A1 |
20070270876 | Kuo et al. | Nov 2007 | A1 |
20070270970 | Trieu | Nov 2007 | A1 |
20070270971 | Trieu et al. | Nov 2007 | A1 |
20070276392 | Beyar et al. | Nov 2007 | A1 |
20070299540 | Ku | Dec 2007 | A1 |
20080004707 | Cragg et al. | Jan 2008 | A1 |
20080015697 | McLeod et al. | Jan 2008 | A1 |
20080021563 | Chudzik | Jan 2008 | A1 |
20080031962 | Boyan et al. | Feb 2008 | A1 |
20080045949 | Hunt et al. | Feb 2008 | A1 |
20080051889 | Hodorek | Feb 2008 | A1 |
20080057128 | Li et al. | Mar 2008 | A1 |
20080075657 | Abrahams et al. | Mar 2008 | A1 |
20080077242 | Reo et al. | Mar 2008 | A1 |
20080077244 | Robinson | Mar 2008 | A1 |
20080097606 | Cragg et al. | Apr 2008 | A1 |
20080103599 | Kim et al. | May 2008 | A1 |
20080114367 | Meyer | May 2008 | A1 |
20080125870 | Carmichael et al. | May 2008 | A1 |
20080131425 | Garcia et al. | Jun 2008 | A1 |
20080145404 | Hill et al. | Jun 2008 | A1 |
20080154372 | Peckham | Jun 2008 | A1 |
20080166329 | Sung et al. | Jul 2008 | A1 |
20080221505 | Betts | Sep 2008 | A1 |
20080269908 | Warburton | Oct 2008 | A1 |
20080279941 | Boyan et al. | Nov 2008 | A1 |
20080279943 | Boyan et al. | Nov 2008 | A1 |
20090043398 | Yakimicki et al. | Feb 2009 | A1 |
20090138015 | Connor et al. | May 2009 | A1 |
20090177205 | McCormack et al. | Jul 2009 | A1 |
20090182421 | Silvestrini et al. | Jul 2009 | A1 |
20090263446 | Boyan et al. | Oct 2009 | A1 |
20100161073 | Thomas et al. | Jun 2010 | A1 |
20100198258 | Heaven et al. | Aug 2010 | A1 |
20100324693 | Hardenbrook | Dec 2010 | A1 |
20100324694 | Hassler et al. | Dec 2010 | A1 |
20110040332 | Culbert et al. | Feb 2011 | A1 |
20110172771 | Boyan et al. | Jul 2011 | A1 |
20110208305 | Malinin | Aug 2011 | A1 |
20110270400 | Kita et al. | Nov 2011 | A1 |
20110318704 | Teichmann | Dec 2011 | A1 |
20120022568 | Koblish | Jan 2012 | A1 |
20120053642 | Lozier | Mar 2012 | A1 |
20120203346 | Kraus | Aug 2012 | A1 |
20130006368 | Walsh et al. | Jan 2013 | A1 |
20130211451 | Wales et al. | Aug 2013 | A1 |
20140214080 | Wales et al. | Jul 2014 | A1 |
20140032169 | Maher et al. | Oct 2014 | A1 |
20150351815 | Wales et al. | Dec 2015 | A1 |
20160038308 | Walsh et al. | Feb 2016 | A1 |
20160287392 | Patrick et al. | Oct 2016 | A1 |
20160287407 | Patrick et al. | Oct 2016 | A1 |
20160302930 | Axelrod et al. | Oct 2016 | A1 |
20170304039 | Eaves, III et al. | Oct 2017 | A1 |
20180185159 | Patrick et al. | Jul 2018 | A1 |
Number | Date | Country |
---|---|---|
20218703 | Mar 2003 | DE |
0222404 | May 1987 | EP |
0222407 | May 1987 | EP |
0346129 | Dec 1989 | EP |
0505634 | Sep 1992 | EP |
0410010 | Oct 1993 | EP |
0411105 | Jun 1995 | EP |
0845480 | Jun 1998 | EP |
0919209 | Jun 1999 | EP |
1287796 | Mar 2003 | EP |
103069781 | Aug 2003 | EP |
1344538 | Sep 2003 | EP |
1584338 | Oct 2005 | EP |
1482996 | Nov 2005 | EP |
02056882 | Mar 1981 | GB |
02128501 | May 1984 | GB |
02-184580 | Jul 1990 | JP |
04053843 | Feb 1992 | JP |
07247365 | Sep 1995 | JP |
11035732 | Feb 1999 | JP |
2005-199054 | Jul 2005 | JP |
2006-101893 | Apr 2006 | JP |
W09000757 | Jul 1990 | WO |
W090007545 | Jul 1990 | WO |
W090010018 | Sep 1990 | WO |
W093016664 | Sep 1992 | WO |
W094001483 | Jan 1994 | WO |
W095025183 | Sep 1995 | WO |
W097006101 | Feb 1997 | WO |
W097046178 | Dec 1997 | WO |
W098002146 | Jan 1998 | WO |
W098050017 | Nov 1998 | WO |
W099025391 | May 1999 | WO |
W099034845 | Jul 1999 | WO |
W000030998 | Jun 2000 | WO |
W000042991 | Jul 2000 | WO |
W000062829 | Oct 2000 | WO |
W000066191 | Nov 2000 | WO |
WOO1002033 | Jan 2001 | WO |
WOO1022902 | Apr 2001 | WO |
WOO1059160 | Aug 2001 | WO |
W001070436 | Sep 2001 | WO |
WOO1064030 | Sep 2001 | WO |
W001091822 | Dec 2001 | WO |
W002009647 | Feb 2002 | WO |
W002030480 | Apr 2002 | WO |
W002064182 | Aug 2002 | WO |
W003030787 | Apr 2003 | WO |
W003092760 | Nov 2003 | WO |
W004060554 | Jul 2004 | WO |
W004101013 | Nov 2004 | WO |
W005077013 | Aug 2005 | WO |
W005077304 | Aug 2005 | WO |
W005097006 | Oct 2005 | WO |
W006018531 | Feb 2006 | WO |
W006019634 | Feb 2006 | WO |
W006030054 | Mar 2006 | WO |
W006034365 | Mar 2006 | WO |
WO2006060416 | Jun 2006 | WO |
WO2007022188 | Feb 2007 | WO |
WO2009052208 | Apr 2009 | WO |
WO2012162552 | Nov 2012 | WO |
Entry |
---|
Andrade et al., “Water as a Biomaterial,” Trans. Am. Soc. Artif. Intern. Organs, 19:1 (1973). |
Ariga et al., “Immobilization of Microorganisms with PVA Hardened by Iterative Freezing and Thawing,” Journal of Fermentation Technology, 65(6): pp. 651-658 (1987). |
Boyan et al., “Effect of Titanium Surface Characteristics on Chondrocytes and Osteoblasts in Vitro,” Cells and Materials, vol. 5, No. 4, pp. 323-335 (1995). |
Boyan et al., “Osteoblast-Mediated Mineral Deposition in Culture is Dependent on Surface Microtopography,” Calcif. Tissue Int., 71:519-529 (2002). |
Bray et al., Poly(vinyl alcohol) Hydrogels for Synthetic Articular Cartilage Material, M. Biomed. Mater. Res., vol. 7, pp. 431-443. |
Brunette, “The Effects of Implant Surface Topography on the Behavior of Cells,” Int. J. Oral Maxillofac Implants, 3:231-240 (1988). |
Chen et al., “Boundary layer infusion of heparin prevents thrombosis and reduces neointimal hyperplasia in venous polytetrafluoroethylene grafts without system anticoagulation,” J. Vascular Surgery, 22:237-247 (1995). |
Chu et al., “Polyvinyl Alcohol Cryogel: An Ideal Phantom Material for MR Studies of Arterial Elasticity,” Magnetic Resonance in Medicine, v. 37, pp. 314-319 (1997). |
Hickey et al., “Mesh size and diffusive characteristics of semicrystalline poly(vinyl alcohol) membranes prepared by freezing/thawing techniques,” Journal of Membrane Science, 107(3), pp. 229-237 (1995). |
Hoffman et al., “Interactions of Blood and Blood Components at Hydrogel Interfaces,” Ann. New York Acad. Sci., 283:372-382 (1977). |
Hunt, Knee Simulation, Creep, and Friction Tests of Poly(Vinyl Alcohol) Hydrogels Manufactured Using Injection Molding and Solution Casting, Thesis for M.S., University of Notre Dame (Jul. 2006). |
Katta et al., “Friction and wear behavior of poly(vinyl alcohol)/poly(vinyl pyrrolidone) hydrogels for articular cartilage replacement,” Journal of Biomedical Materials Research, vol. 83A, pp. 471-479 (2007). |
Kieswetter et al., “The Role of Implant Surface Characteristics in the Healing of Bone,” Crit. Rev. Oral Biol. Med., 7(4):329-345 (1996). |
Kieswetter et al., “Surface roughness modulates the local production of growth factors and cytokines by osteoblast-like MG-63 cells,” Journal of Biomedical Materials Research, vol. 32, pp. 55-63 (1996). |
Kobayashi et al., “Characterization of a polyvinyl alcohol-hydrogel artificial articular cartilage prepared by injection molding,” J. Biomater. Sci. Polymer Edn., 15(6): 741-751 (2003). |
Kobayashi et al., “Development of an artificial meniscus using polyvinyl alcohol-hydrogel for early return to, and continuance of, athletic life in sportspersons with severe meniscus injury. I: mechanical evaluation.” The Knee, 10 (2003); 47-51. |
Kohavi et al., “Markers of primary mineralization are correlated with bone-bonding ability of titanium or stainless steel in vivo,” Clin. Oral. Impl. Res., 6:1-13 (1995). |
Koutsopoulos et al., “Calcification of porcine and human cardiac valves: testing of various inhibitors for antimineralization,” J. Mater. Sci. Mater. Med., 9:421-424 (1998). |
Kwak, BK, et al., “Chitin-based Embolic Materials in the Renal Artery of Rabbits: Pathologic Evaluation of an Absorbable Particulate Agent”, Radiology, 236:151-158 (2005). |
Landolt et al., “Electrochemical micromachining, polishing and surface structuring of metals: fundamental aspects and new developments”, Elsevier Science Ltd., pp. 3185-3201 (2003). |
Lazzeri et al., “Physico-chemical and mechanical characterization of hydrogels of poly(vinyl alcohol) and hyaluronic acid,” J. Mater. Sci. In Med., 5:862-867 (1994). |
Liao et al., “Response of rat osteoblast-like cells to microstructured model surfaces in vitro,” Biomaterials, 24, pp. 649-654 (2003). |
Lozinsky et al., “Study of cryostructurization of polymer systems. VII. Structure formation under freezing of poly(vinyl alcohol) acqueous solutions,” Colloid & Polymer Science, vol. 264, pp. 19-24 (1986). |
Lozinsky et al., “Study of Cryostructuration of Polymer Systems. XII. Poly(vinyl alcohol) Cryogels: Influence of Low-Molecular Electrolytes,” Journal of Applied Polymer Science, vol. 61, pp. 1991-1998 (1996). |
Lozinsky et al., “Study of Cryostructuration of Polymer Systems. XI. The Formation of PVA Cryogels by Freezing-Thawing the Polymer Aqueous Solutions Containing Additives of Some Polyols,” Journal of Applied Polymer Science, vol. 58, pp. 171-177 (1995). |
Lozinsky et al., “Poly(vinyl alcohol) cryogels employed as matrices for cell immobilization. 2. Entrapped cells resemble porous fillers in their effects on the properties of PVA-cryogel carrier,” Enzyme and Microbial Technology, vol. 20, No. 3, pp. 182-190 (1997). |
Lozinsky et al., “Poly(vinyl alcohol) cryogels employed as matrices for cell immobilization. 3. Overview of recent research and developments,” Enzyme and Microbial Technology, vol. 23, No. 3-4, pp. 227-242 (1998). |
Lusta et al., “Immobilization of fungus Aspergil/us sp. by a novel cryogel technique for production of extracellular hydrolytic enzymes”, Process Biochemistry, vol. 35, pp. 1177-1182 (2000). |
Ma et al., “Friction Properties of novel PVP/PVA blend hydrogels as artificial cartilage,” Journal of Biomedical Materials Research, vol. 93A, pp. 1016-1019 (2010). |
Martin et al., “Effect of titanium surface roughness on proliferation, differentiation, and protein synthesis of human osteoblast-like cells (MG63),” Journal of Biomedical Materials Research, vol. 29, pp. 389-401 (1995). |
Nagura et al., “Structure of poly(vinyl alcohol) hydrogel prepared by repeated freezing and melting,” Polymer, 30:762-765 (1989). |
Nakashima et al., “Study on Wear Reduction Mechanisms of Artificial Cartilage by Synergistic Protein Boundary Film Formation,” Japan Soc'y of Mech. Eng'r Int'l J., Series C, vol. 48, No. 4, pp. 555-561 (2005). |
Oka et al., “Development of an Artificial Articular Cartilage”, Clinical Materials, vol. 6, pp. 361-381 (1990). |
Ong et al., “Osteoblast Responses to BMP-2-Treated Titanium In Vitro,” The International Journal of Oral & Maxillofacial Implants, vol. 12, No. 5, pp. 649-654 (1997). |
Peppas et al., “Reinforced uncrosslinked poly(vinyl alcohol) gels produced by cyclic freezing-thawing processes: a short review,” Journal of Controlled Release, 16(3): 305-310 (1991). |
Peppas et al., “Structure of Hydrogels by Freezing-Thawing Cyclic Processing,” Bulletin of the American Physical Society, 36:582 (1991). |
Peppas et al., “Controlled release from poly(vinyl alcohol) gels prepared by freezing-thawing processes,” Journal of Controlled Release, vol. 18, pp. 95-100 (1992). |
Peppas et al., “Ultrapure poly(vinyl alcohol) hydrogels with mucoadhesive drug delivery characteristics,” European Journal of Pharmaceutics and Biopharmaceutics, 43(1): 51-58 (1997). |
Ratner et al., Biomaterials Science an Introduction to Materials in Medicine, Academic Press, pp. 52, 53, & 62 (1996). |
Ricciardi et al., “Structure and Properties of Poly(vinyl alcohol) Hydrogels Obtained by Freeze/Thaw Techniques,” Macromol. Symp., 222: 49-63 (2005). |
Schwartz et al., “Underlying Mechanisms at the Bone-Biomaterial Interface,” Journal of Cellular Biochemistry, 56:340-347 (1994). |
Singh et al., “Polymeric Hydrogels: Preparation and Biomedical Applications,” J. Sci. Ind. Res., 39:162-171 (1980). |
Stauffer et al., “Poly(vinyl alcohol) hydrogels prepared by freezing-thawing cyclic processing,” Polymer 33(1818):3932-3936 (1992). |
Stewart et al., “Protein release from PVA gels prepared by freezing and thawing techniques,” Proc. Int. Symp. Controlled Release Bioact. Mater., 26, 1004-1005 (1999). |
Szczesna-Antezak et al., “Bacillus subtilis cells immobilised in PVA-cryogels,” Biomolecular Engineering, vol. 17, pp. 55-63 (2001). |
The American Heritage® Science Dictionary [online], Houghton Mifflin Company, 2002 [retrieved on Jun. 3, 2008]. Retrieved from the internet: <URL: http://dictionary.reference.com/browse/pore>. |
Watase et al., “Rheological and DSC Changes in Poly(vinyl alcohol) Gels Induced by Immersion in Water,” Journal of Polymer Science, Polym. Phys. Ed, 23(9): 1803-1811 (1985). |
Watase et al., “Thermal and rheological properties of poly(vinyl alcohol) hydrogels prepared by repeated cycles of freezing and thawing,” Makromol. Chem., v. 189, pp. 871-880 (1988). |
Willcox et al., “Microstructure of Poly(vinyl alcohol) Hydrogels Produced by Freeze/Thaw Cycling,” Journal of Polymer Sciences: Part B: Polymer Physics, vol. 37, pp. 3438-3454 (1999). |
WordNet® 3.0 [online], Princeton University, 2006 [retrieved on Aug. 6, 2008]. Retrieved from the Internet: <URL: http://dictionary.reference.com/browse/mesh>. |
Yamaura et al., “Properties of Gels Obtained by Freezing/Thawing of Poly(vinyl Alcohol)/Water/Dimethyl Sulfoxide Solutions,” J. Appl. Polymer Sci., 37:2709-2718 (1989). |
Yokoyama et al., “Morphology and structure of highly elastic poly(vinyl alcohol) hydrogel prepared by repeated freezing-and-melting”, Colloid & Polymer Science, vol. 264, No. 7, pp. 595-601 (1986). |
Zheng-Qiu et al., “The development of artificial articular cartilage—PVA-hydrogel,” Bio-Medical Materials and Engineering, vol. 8, pp. 75-81 (1998). |
Number | Date | Country | |
---|---|---|---|
20220168107 A1 | Jun 2022 | US |
Number | Date | Country | |
---|---|---|---|
61490507 | May 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15386756 | Dec 2016 | US |
Child | 16453020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16453020 | Jun 2019 | US |
Child | 17651452 | US | |
Parent | 14826918 | Aug 2015 | US |
Child | 15386756 | US | |
Parent | 13480272 | May 2012 | US |
Child | 14826918 | US |